FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number: Estimated average burden

0.5

hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* JOHNSON FRANKLIN P JR				2. Issuer Name and Ticker or Trading Symbol AMGEN INC [AMGN]									Relationshi neck all app X Direc	olicable)	rting Pe		Issuer Owner			
(Last) ONE AM	(Fi	rst) (I	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 08/02/2005									Offic below	eer (give title w)			Other (specify below)		
(Street) THOUSA OAKS (City)	C.		01320-1 Zip)	799	4. If A	Ameno	dment,	Date o	of Original Filed (Month/Day/Year)						Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a 5)					6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership					
									Code	v	Amount	(A) (D)	or Pi	ice	Transaci (Instr. 3	tion(s)			(Instr. 4)	
CCPR														4(1)				By Partnership		
Common	Stock			08/02/2	005				J ⁽²⁾		100,000	Г		\$0	400	400,000			By Partnership	
Common	Stock			08/02/2	005				J ⁽²⁾		50,000	A	A \$		1,683,061				Revocable Trust	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, Transaction of		ative rities ired sed	6. Date	ion Da		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amount or Number of		r. 3	8. Price of Derivative Security (Instr. 5) Securitie Beneficia Owned Following Reported Transacti (Instr. 4)		e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				

Explanation of Responses:

2. (FJP 08/05 Dist) On August 2, 2005, Asset Management Partners ("AMP") distributed shares of Amgen Common Stock to the partners of the partnership. Accordingly, 50,000 shares are now held indirectly by the Johnson Revocable Trust, and an aggregate of 50,000 shares were distributed to the other partners. AMP, of which the reporting person is the general partner, holds 400,000 shares of Amgen Common Stock. The reporting person disclaims beneficial ownership of the securities held by AMP, and the reporting herein of such securities shall not be construed as an admission that the reporting person is the beneficial owner of any such securities for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

> 08/02/2005 /s/ Franklin P Johnson, Jr.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1. (}FPJ-CCPR) Contractual contingent payment rights arising from the purchase by Amgen Inc. of four Class A interests of Amgen Clinical Partners, L.P.